RxDoctor Payments Data

Hannah Mathew, MD

Endocrinology, Diabetes & Metabolism · Framingham, MANPI 1225371230

Payments from drug & device makers

$322in general payments, 2019–2025

Across 12 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$57
  • Abbott$56
  • Novo Nordisk$44
  • Lilly USA, LLC$36
  • Amgen$31
  • Boehringer Ingelheim$29
  • plus $69 from 3 others

What the payments were for

  • Food & beverage$322100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$322 in reported general payments places this provider in the 35th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$164,113
Medicare patients
743
Services billed
2,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$343,668
TrulicityDulaglutide192$335,241
JardianceEmpagliflozin160$220,747
MounjaroTirzepatide93$119,052
FarxigaDapagliflozin Propanediol69$104,948
JanuviaSitagliptin Phosphate75$85,348
RybelsusSemaglutide51$76,876
TradjentaLinagliptin63$64,293
Humalog Kwikpen U-200Insulin Lispro25$52,298
Teriparatide15$48,108
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog64$39,317
Tresiba Flextouch U-200Insulin Degludec35$34,440
Fiasp FlextouchInsulin Aspart (Niacinamide)25$31,418
Lantus SolostarInsulin Glargine,hum.Rec.Anlog194$26,828
Tresiba Flextouch U-100Insulin Degludec28$23,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Baqsimi$36$466,692313 claims
Novo NordiskOzempic, Rybelsus$44$420,544200 claims
Boehringer IngelheimJardiance, Tradjenta$29$285,039223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

Other endocrinology, diabetes & metabolism in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →